Search Results

Can-Fite BioPharma Ltd. announces that its VP of Business Development, Dr. Sari Fishman, will hold 23 partnering meetings with Biotech & Pharma companies, who showed interest in partnering with Can-Fite.

Can-Fite BioPharma Ltd. today announced an update on the status of its oncological lead drug candidate, Namodenoson in the treatment of advanced liver cancer.

Can-Fite BioPharma Ltd. is pleased to invite investors to a webinar on June 6, 2024, at 4:15 p.m. ET.

Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, announces that company scientists came up with breakthrough findings showing that the anti-cancer and protective effects in the liver are conferred via the signalling protein adiponectin.

Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, announced that it received an approval from the Institutional Review Board of Rabin Medical Center, a leading medical institution in Israel where the study will be conducted.

Can-Fite BioPharma Ltd. announced financial results and clinical updates for the twelve months ended December 31, 2023.

Can-Fite BioPharma Ltd. reported that the International Journal of Molecular Sciences published a scientific review by independent scientists summarizing >50 publications from scientists all over the world stating that piclidenoson and namodenoson have a positive effect on heart diseases.

Can-Fite BioPharma Ltd. announces that the U.S. Food and Drug Administration has granted Investigational New Drug clearance for Namodenoson, for the treatment of patients with metabolic dysfunction-associated steatohepatitis, also known as non-alcoholic steatohepatitis, for the Company’s ongoing Phase IIb clinical study.

Can-Fite BioPharma Ltd. today announced it published an article in the Experimental and Therapeutic Medicine Journal, titled “Long-term complete response to namodenoson in liver cancer with Child-Pugh B cirrhosis: A case report” (Link).

Can-Fite BioPharma Ltd today announced that it has expanded its out licensing transaction with Ewopharma AG. to include the pancreatic cancer indication of Can-Fite.